Form 8-K - Current report:
SEC Accession No. 0001193125-25-250674
Filing Date
2025-10-27
Accepted
2025-10-27 07:00:13
Documents
13
Period of Report
2025-10-26
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d36426d8k.htm   iXBRL 8-K 34968
2 EX-99.1 d36426dex991.htm EX-99.1 30634
  Complete submission text file 0001193125-25-250674.txt   189470

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fate-20251026.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20251026_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20251026_pre.xml EX-101.PRE 10830
16 EXTRACTED XBRL INSTANCE DOCUMENT d36426d8k_htm.xml XML 3531
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 251417419
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)